Research Papers:

The accuracy of microRNA-210 in diagnosing lung cancer: a systematic review and meta-analysis

Huqin Yang, Huijuan Wang, Chao Zhang and Zhaohui Tong _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:63283-63293. https://doi.org/10.18632/oncotarget.11446

Metrics: PDF 2242 views  |   HTML 2375 views  |   ?  


Huqin Yang1,*, Huijuan Wang1,*, Chao Zhang1, Zhaohui Tong1

1Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China

*These authors contributed equally to this work

Correspondence to:

Zhaohui Tong, email: [email protected]

Keywords: microRNA-210, lung cancer, diagnosis, meta-analysis, systematic review

Received: May 20, 2016     Accepted: August 13, 2016     Published: August 20, 2016


Studies examining the diagnostic value of microRNA-210 for lung cancer have yielded inconsistent results. Here, we performed a meta-analysis to assess the diagnostic accuracy of microRNA-210 for lung cancer. Nine eligible studies involving 993 patients (554 lung cancer patients and 439 non-cancer patients) were independently identified, and the quality of these studies was assessed according to Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) guidelines. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.66 (95% CI, 0.57 to 0.75), 0.82 (95% CI, 0.72 to 0.89), 3.64 (95% CI, 2.54 to 5.21), 0.41 (95% CI, 0.34 to 0.51) and 8.78 (95% CI, 6.10 to 12.66), respectively. The area under the summary receiver operator characteristic curve was 0.80 (95% CI, 0.76 to 0.83). These results indicated that microRNA-210 had moderate diagnostic value for lung cancer. Additional prospective studies are needed to confirm the diagnostic value of microRNA-210.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11446